Rising immunisation demand and manufacturing complexity drive sustained outsourcing
London, UK – 28 January 2026 – The global vaccine contract manufacturing market is estimated at US$3,947.4 million in 2026 and is projected to grow at a CAGR of 10.9% over the forecast period 2026-2036, reaching US$11,065.6 million by 2036. The growth is driven by expanding immunisation programmes, greater platform diversity, and a greater reliance on specialist contract manufacturing partners.
Key Market Drivers
- Expansion of national and international immunisation and booster programmes
- Growing technological complexity across vaccine platforms
- Increased outsourcing to manage capital intensity and regulatory risk
- Demand for scalable and geographically resilient supply chains
“The vaccine contract manufacturing market is evolving towards greater platform diversity, regional resilience and deeper collaboration between sponsors and specialist CMOs,” said Visiongain.
Regulatory and Trade Impact
US trade tariffs are expected to influence the vaccine contract manufacturing market through higher input costs, procurement complexity and supply chain realignment. Tariffs affecting bioprocessing equipment, single-use systems and specialist materials may compress margins and extend validation timelines, while encouraging dual sourcing and regional capacity strategies. Over time, this is likely to accelerate selective localisation, particularly for conventional vaccine platforms, while highly specialised technologies remain concentrated in advanced facilities.
Visiongain notes that this shift is creating a more geographically fragmented market, with greater emphasis on regulatory readiness, supply resilience and end-to-end execution reliability.
Competitive Highlights
Leading companies operating in the vaccine contract manufacturing market include Ajinomoto Bio-Pharma, Catalent, Charles River Laboratories, Curia Global, Emergent BioSolutions, FUJIFILM Holdings Corporation, IDT Biologika, Lonza, Recipharm AB and WuXi Biologics. Recent activity has focused on capacity expansion, long-term supply agreements, advanced manufacturing technologies, and strategic collaborations to support complex, multi-platform vaccine pipelines.
Recent Developments
- Expansion of new manufacturing suites and biotech facilities aimed at increasing capacity for next-generation vaccines
- Strategic long-term supply agreements between CMOs and vaccine developers to secure production capacity
- Implementation of advanced single-use bioprocessing systems and digital manufacturing technologies to improve flexibility and reduce changeover times
- Partnerships and acquisitions in key regions to strengthen regional footprint and regulatory compliance capabilities
About the Report
The Vaccine Contract Manufacturing Market Report 2026-2036 provides detailed forecasts by vaccine type, process, end use, operation stage and company size, alongside regional and national market analysis. The report examines the impact of US trade tariffs, evolving manufacturing models and competitive strategies across the global market.
About Visiongain
Founded in 1998, Visiongain is a trusted publisher of independent, analyst-led market intelligence. For more than two decades, Visiongain has delivered rigorous research, data-driven forecasts, and strategic insight across global industries and emerging markets.
Visiongain’s research is designed to support evidence-based decision-making across investment, procurement, and long-term strategic planning. Combining deep sector expertise with robust methodologies, Visiongain helps decision-makers understand market dynamics, evaluate risk, and identify structural opportunities shaping future growth.
Company Contact
Email: [email protected]
Phone: +44 (0)20 7336 6100
Website: www.visiongain.com
- Vaccine Contract Manufacturing Market Report 2026-2036